A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : DOX

Search Conditions:
Search Keyword : DOX
Search Method : Exact match.
Research Area:

Results:  
Hit abbr.: 2 kinds.
(Click one to see its hit entries.)

(Appearance freq, Descending)
Abbreviation: DOX
Appearance Frequency: 12914 time(s)
Long forms: 131

Display Settings:
[Display Entries]
Long Form, 100 entries
    (Appearance freq, Descending)
Long Form, all entries
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
doxorubicin
(11118 times)
Pharmacology
(1839 times)
MDR (569 times)
ROS (546 times)
P-gp (390 times)
1979 Effects of daunorubicin and doxorubicin, free and associated with DNA, on hemopoietic stem cells.
doxycycline
(977 times)
Molecular Biology
(122 times)
TET (69 times)
TRE (27 times)
rtTA (26 times)
1993 Effect of tetracyclines which have metalloproteinase inhibitory capacity on basal and heparin-stimulated bone resorption by chick osteoclasts.
doxorubicin hydrochloride
(516 times)
Chemistry
(110 times)
NIR (31 times)
NPs (28 times)
MSNs (23 times)
1986 Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease.
doxazosin
(30 times)
Pharmacology
(6 times)
ALF (4 times)
BP (4 times)
BPH (3 times)
1987 A 24-week multicenter double-blind study of doxazosin and hydrochlorothiazide in patients with mild to moderate essential hypertension.
doxepin
(27 times)
Pharmacology
(8 times)
AMI (8 times)
IMI (5 times)
DDOX (4 times)
1978 Doxepin kinetics.
copolymer-doxorubicin
(20 times)
Pharmacology
(8 times)
HPMA (10 times)
MW (2 times)
RAFT (2 times)
1999 Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
drug-doxorubicin
(16 times)
Pharmacology
(4 times)
MDR (2 times)
PTT (2 times)
ROS (2 times)
2002 Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
dioxygenase
(14 times)
Biochemistry
(8 times)
AOS (6 times)
LDS (5 times)
EAS (3 times)
1994 Construction of hybrid biphenyl (bph) and toluene (tod) genes for functional analysis of aromatic ring dioxygenases.
docetaxel
(13 times)
Biochemistry
(3 times)
PCa (2 times)
3'UTRs (1 time)
AEs (1 time)
2009 Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma.
10  doxycycline hyclate
(12 times)
Pharmacology
(2 times)
beta-CD (1 time)
CAA (1 time)
CNC (1 time)
2007 Intra-articular administration of doxycycline in calves.
11  doxycycline hydrochloride
(11 times)
Environmental Health
(4 times)
TYT (3 times)
BET (2 times)
XRD (2 times)
2000 Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions.
12  doxorubicin HCl
(7 times)
Pharmacology
(2 times)
PLLA (2 times)
CEL (1 time)
CNTs (1 time)
2010 Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
13  doxylamine succinate
(7 times)
Chemistry Techniques, Analytical
(2 times)
PYR (4 times)
RP-HPLC (2 times)
CAF (1 time)
1999 Simultaneous determination of pyridoxine hydrochloride and doxylamine succinate from tablets by ion pair reversed-phase high-performance liquid chromatography (RP-HPLC).
14  docetaxel plus oxaliplatin and capecitabine
(5 times)
Neoplasms
(2 times)
ORR (2 times)
CR (1 time)
DCF (1 time)
2010 [Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial].
15  doxazosin mesylate
(5 times)
Biochemistry
(2 times)
LOD (2 times)
TER (2 times)
ALF (1 time)
2002 Flow injection analysis of doxazosin mesylate using UV-detection.
16  Doxepin hydrochloride
(4 times)
Chemistry Techniques, Analytical
(1 time)
ASM (2 times)
Cer (2 times)
TCAs (2 times)
2017 Doxepin Mitigates Noise-induced Neuronal Damage in Primary Auditory Cortex of Mice via Suppression of Acid Sphingomyelinase/Ceramide Pathway.
17  1,4-dioxane
(3 times)
Chemistry
(2 times)
BSLA (1 time)
cryo-TEM (1 time)
DLS (1 time)
2007 Effect of organic solvents on J aggregation of pseudoisocyanine dye at mica/water interfaces: morphological transition from three-dimension to two-dimension.
18  doxycycline gel
(3 times)
Dentistry
(2 times)
SRP (2 times)
Aa (1 time)
CAL (1 time)
2005 Non-surgical periodontal therapy with adjunctive topical doxycycline: a double-masked, randomized, controlled multicenter study. II. Microbiological results.
19  pectin-doxorubicin
(3 times)
Pharmacology
(2 times)
BC2Tama (1 time)
DOXPCB (1 time)
GI (1 time)
2018 Effect of lutein and doxorubicin combinatorial therapy on S180 cell proliferation and tumor growth.
20  (5,5-(2)H(2))-deoxy-d-xylose
(2 times)
Chemistry
(2 times)
enantio-MDGC-MS (1 time)
SBSE (1 time)
2002 Differential incorporation of 1-deoxy-D-xylulose into (3S)-linalool and geraniol in grape berry exocarp and mesocarp.
21  acute-doxorubicin
(2 times)
Cardiology
(1 time)
EPC (1 time)
HCC (1 time)
TPO (1 time)
2011 Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks.
22  agents-doxorubicin
(2 times)
Medicine
(1 time)
CPT (1 time)
gamma-GCS (1 time)
HA (1 time)
2013 Purine nucleoside analog--sulfinosine modulates diverse mechanisms of cancer progression in multi-drug resistant cancer cell lines.
23  anthracyclines-doxorubicin
(2 times)
Pharmacology
(1 time)
CTAB (1 time)
DAU (1 time)
DOSY (1 time)
2015 Low-density lipoprotein peptide-combined DNA nanocomplex as an efficient anticancer drug delivery vehicle.
24  DOX loaded chitosan/carboxymethyl chitosan nanogels
(2 times)
Biochemistry
(1 time)
GI (1 time)
MMS (1 time)
P-gp (1 time)
2016 Multilayer micro-dispersing system as oral carriers for co-delivery of doxorubicin hydrochloride and P-gp inhibitor.
25  doxanthrine
(2 times)
Psychopharmacology
(2 times)
AUC (1 time)
DHX (1 time)
PD (1 time)
2008 Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors.
26  doxantrazole
(2 times)
Gastroenterology
(2 times)
FAE (2 times)
CRHR (1 time)
HRP (1 time)
2010 Stress-induced barrier disruption of rat follicle-associated epithelium involves corticotropin-releasing hormone, acetylcholine, substance P, and mast cells.
27  doxorubicin base
(2 times)
Nanotechnology
(1 time)
CMC (1 time)
CSO (1 time)
CSO-LA (1 time)
2010 Linoleic acid-grafted chitosan oligosaccharide micelles for intracellular drug delivery and reverse drug resistance of tumor cells.
28  doxorubicin group
(2 times)
Pharmacology
(1 time)
BHB (1 time)
Sham (1 time)
2021 Cardioprotective Roles of beta-Hydroxybutyrate Against Doxorubicin Induced Cardiotoxicity.
29  doxorubicin-based chemotherapy
(2 times)
General Surgery
(1 time)
CD (1 time)
CHF (1 time)
DLBCL (1 time)
2004 The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.
30  doxorubicin-induced
(2 times)
Medicine
(1 time)
DOX group (1 time)
HE (1 time)
HO-1 (1 time)
2011 Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy.
31  (DSPE)-doxorubicin
(1 time)
Biomedical Engineering
(1 time)
DSPE (1 time)
DSPE-mPEG2000 (1 time)
Tet (1 time)
2017 Hybrid Prodrug Nanoparticles with Tumor Penetration and Programmed Drug Activation for Enhanced Chemoresistant Cancer Therapy.
32  (Tf-M-DOX/PSO), coencapsulating doxorubicin
(1 time)
Geriatrics
(1 time)
MDR (1 time)
PSO (1 time)
2020 Reversal of multidrug resistance in leukemia cells using a transferrin-modified nanomicelle encapsulating both doxorubicin and psoralen.
33  (vc)-doxorubicin
(1 time)
Nanotechnology
(1 time)
ADCs (1 time)
BSA (1 time)
EGFR (1 time)
2021 EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy.
34  1,3-dioxolan-4-one
(1 time)
Chemistry
(1 time)
--- 2022 Sustainability and Polyesters: Beyond Metals and Monomers to Function and Fate.
35  1-(4-X-2,5-dimethoxyphenyl)-2-aminopropane
(1 time)
Chemistry
(1 time)
XBs (1 time)
2021 5-HT2 Receptor Subfamily and the Halogen Bond Promise.
36  2,5-dimethoxyamphetamines
(1 time)
Chemistry Techniques, Analytical
(1 time)
CID (1 time)
NLFs (1 time)
NPS (1 time)
2017 Characterization of hallucinogenic phenethylamines using high-resolution mass spectrometry for non-targeted screening purposes.
37  alpha'-dimercapto-o-xylene
(1 time)
Toxicology
(1 time)
BDT (1 time)
DDOX (1 time)
DMPA (1 time)
1990 Structural influences on intracellular cadmium mobilization by dithiols.
38  An-PEG-DOX-AuNPs, was loaded with doxorubicin
(1 time)
Biomedical Engineering
(1 time)
LRP1 (1 time)
2014 Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles.
39  analogs--doxorubicin
(1 time)
Biology
(1 time)
ACR (1 time)
1998 Structurally different anthracyclines provoke different effects on cell cycle and tumor B cell differentiation.
40  BR96-doxorubicin
(1 time)
Antineoplastic Agents
(1 time)
--- 1997 Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
41  cisplatin-doxorubicin
(1 time)
Carbohydrates
(1 time)
--- 2016 Cisplatin-crosslinked glutathione-sensitive micelles loaded with doxorubicin for combination and targeted therapy of tumors.
42  cycler-doxorubicin
(1 time)
Chemistry
(1 time)
FA (1 time)
TPP (1 time)
2012 Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes.
43  deoxy-D-xylulose
(1 time)
Medicine
(1 time)
--- 1999 Induced biosynthesis of insect semiochemicals in plants.
44  deoxycholate
(1 time)
Cell Biology
(1 time)
--- 1975 [Some properties of preparations of Na+ and k+-ATPase treated with deoxycholate].
45  deoxyglucose
(1 time)
Obstetrics
(1 time)
AIB (1 time)
Cd (1 time)
VitB12 (1 time)
1984 Effects of cadmium on the placental uptake and transport to the fetus of nutrients.
46  DePQu-DOX NPs coloading doxorubicin
(1 time)
Biocompatible Materials
(1 time)
ATP (1 time)
QU (1 time)
2020 Tissue-Specific Regulation of Reactive Oxygen Species by an ATP-Responsive Nanoregulator Enhances Anticancer Efficacy and Reduces Anthracycline-Induced Cardiotoxicity.
47  desferrioxamine
(1 time)
Biochemistry
(1 time)
5 alpha-OOH (1 time)
BHT (1 time)
1988 Ascorbate-enhanced lipid peroxidation in photooxidized cell membranes: cholesterol product analysis as a probe of reaction mechanism.
48  develop functional Eu/MBGs by combining excellent apatite-mineralization ability, controllable drug
(1 time)
--- 2018 Design and Evaluation of Europium Containing Mesoporous Bioactive Glass Nanospheres: Doxorubicin Release Kinetics and Inhibitory Effect on Osteosarcoma MG 63 Cells.
49  developed a heterogeneous oxidant, i.e., a solid redox polymer
(1 time)
Biology
(1 time)
BV (1 time)
NOMs (1 time)
2017 Highly efficient and environmentally benign As(III) pre-oxidation in water by using a solid redox polymer.
50  Dewar- o-xylylene
(1 time)
Chemistry
(1 time)
PDOX (1 time)
POX (1 time)
2018 Polymer Valence Isomerism: Poly(Dewar- o-xylylene)s.
51  dexamethasone-oxetanone
(1 time)
Biochemistry
(1 time)
HTC (1 time)
TAT (1 time)
1986 Analysis of the relation between receptor binding affinity and antagonist efficacy of antiglucocorticoids.
52  dextran-doxorubicin
(1 time)
Pharmacological Phenomena
(1 time)
ATRP (1 time)
TME (1 time)
2020 The design and synthesis of dextran-doxorubicin prodrug-based pH-sensitive drug delivery system for improving chemotherapy efficacy.
53  dicloxacillin
(1 time)
Biochemistry
(1 time)
AMP (1 time)
CL (1 time)
OX (1 time)
2016 Radical-scavenging activity of penicillin G, ampicillin, oxacillin, and dicloxacillin.
54  different concentration of the B. persica extract
(1 time)
Molecular Biology
(1 time)
GC-MS (1 time)
MTT (1 time)
2019 The Blepharis persica seed hydroalcoholic extract synergistically enhances the apoptotic effect of doxorubicin in human colon cancer and gastric cancer cells.
55  dioxyxylene
(1 time)
Biochemistry
(1 time)
--- 2000 Polymer-supported and chemoenzymatic synthesis of the Neisseria meningitidis pentasaccharide: a methodological comparison.
56  diphenol oxidase
(1 time)
Molecular Biology
(1 time)
POX (1 time)
1991 Drosophila melanogaster diphenol oxidase A2: gene structure and homology with the mouse mast-cell tum- transplantation antigen, P91A.
57  dissolved oxygen multi-electrode sensor
(1 time)
Biotechnology
(1 time)
PCA (1 time)
2006 Detection and identification of bacteria using antibiotic susceptibility and a multi-array electrochemical sensor with pattern recognition.
58  DMSP-amine oxidase
(1 time)
Physiology
(1 time)
DMSP (1 time)
DMSP-amine (1 time)
SDC (1 time)
2000 Biochemical evidence for two novel enzymes in the biosynthesis of 3-dimethylsulfoniopropionate in Spartina alterniflora.
59  DNA origami/doxorubicin
(1 time)
Biocompatible Materials
(1 time)
--- 2018 Time-lapse live cell imaging to monitor doxorubicin release from DNA origami nanostructures.
60  docking, ONIOM, and XO
(1 time)
Chemistry
(1 time)
--- 2017 Structure-Based Rational Design of Novel Inhibitors Against Fructose-1,6-Bisphosphate Aldolase from Candida albicans.
61  DOX by confocal microscopy and fluorescence spectrophotometry showed that M-MSN
(1 time)
Biomedical Engineering
(1 time)
FA (1 time)
2016 Folate-Functionalized Magnetic-Mesoporous Silica Nanoparticles for Drug/Gene Codelivery To Potentiate the Antitumor Efficacy.
62  DOX combined with olaratumab (OLA)
(1 time)
Biochemistry
(1 time)
PAL (2 times)
PAZ (2 times)
DOC (1 time)
2019 Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model.
63  DOX concentration
(1 time)
Chemistry Techniques, Analytical
(1 time)
ECS (1 time)
2016 A general strategy to facilely design ratiometric electrochemical sensors in electrolyte solution by directly using a bare electrode for dual-signal sensing of analytes.
64  DOX group
(1 time)
IL-1beta (1 time)
LC3B (1 time)
MDA (1 time)
2023 Modulatory Role of Autophagy in Metformin Therapeutic Activity toward Doxorubicin-Induced Nephrotoxicity.
65  DOX model group
(1 time)
Biomedical Engineering
(1 time)
H2S (1 time)
SD (1 time)
2021 H2S improves doxorubicin-induced myocardial fibrosis by inhibiting oxidative stress and apoptosis via Keap1-Nrf2.
66  DOX prodrug
(1 time)
Biocompatible Materials
(1 time)
MDR (1 time)
PTX (1 time)
2021 Novel multi-stimuli responsive functionalized PEG-based co-delivery nanovehicles toward sustainable treatments of multidrug resistant tumor.
67  DOX release and tumor accumulation of mLTSL
(1 time)
Pharmacology
(1 time)
IONPs (1 time)
LTSL (1 time)
MRI (1 time)
2021 PD1 blockade potentiates the therapeutic efficacy of photothermally-activated and MRI-guided low temperature-sensitive magnetoliposomes.
68  DOX release from pRGO@MS
(1 time)
Biomedical Engineering
(1 time)
DA (1 time)
GO (1 time)
HA (1 time)
2016 Mesoporous Silica Coated Polydopamine Functionalized Reduced Graphene Oxide for Synergistic Targeted Chemo-Photothermal Therapy.
69  DOX release from YSPMOs
(1 time)
Nanotechnology
(1 time)
CuS (1 time)
PTT (1 time)
YSPMOs (1 time)
2018 Fabrication of multifunctional triple-responsive platform based on CuS-capped periodic mesoporous organosilica nanoparticles for chemo-photothermal therapy.
70  DOX treated
(1 time)
Antineoplastic Agents
(1 time)
US (1 time)
2007 Combination of doxorubicin and low-intensity ultrasound causes a synergistic enhancement in cell killing and an additive enhancement in apoptosis induction in human lymphoma U937 cells.
71  DOX was released from HA-HMCN
(1 time)
Nanotechnology
(1 time)
GQD (1 time)
HA (1 time)
HMCN (1 time)
2018 Graphene quantum dots-gated hollow mesoporous carbon nanoplatform for targeting drug delivery and synergistic chemo-photothermal therapy.
72  DOX, SIM, or a combination of them
(1 time)
DMPS (1 time)
POPC (1 time)
SIM (1 time)
2022 Simvastatin Coadministration Modulates the Electrostatically Driven Incorporation of Doxorubicin into Model Lipid and Cell Membranes.
73  DOX-DCMs
(1 time)
Nanotechnology
(1 time)
AUC (1 time)
NAC (1 time)
2018 Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma.
74  DOX-HAP
(1 time)
Neoplasms
(1 time)
DOX-HAP (1 time)
HAP (1 time)
1993 Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer.
75  DOX-loaded CS/CMCS nanoparticles
(1 time)
Chemistry
(1 time)
CMCS (1 time)
CS (1 time)
2013 Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: in vitro and in vivo evaluation.
76  DOX-loaded PGMNs
(1 time)
Pharmacology
(1 time)
PGMNs (2 times)
2010 PEG-modified GoldMag nanoparticles (PGMNs) combined with the magnetic field for local drug delivery.
77  DOX-MSN-S-S-PNIPAM compared to the free drug
(1 time)
Technology, Pharmaceutical
(1 time)
ATRP (1 time)
BET (1 time)
DLS (1 time)
2023 Enzyme and Thermo Dual-stimuli Responsive DOX Carrier Based on PNIPAM Conjugated Mesoporous Silica.
78  DOX-treated mice
(1 time)
Cachexia
(1 time)
sACVR2B-Fc (1 time)
2017 Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
79  DOX-treated sedentary
(1 time)
CON (1 time)
ET (1 time)
FS (1 time)
2021 Endurance Exercise Training Prevents Elevation of Soluble ST2 in Mice with Doxorubicin-Induced Myocardial Injury.
80  DOX/NP
(1 time)
DLE (1 time)
EE (1 time)
PDI (1 time)
2020 Characterization and targeting ability evaluation of cell-penetrating peptide LyP-1 modified alginate-based nanoparticles.
81  Doxacurium
(1 time)
Anesthesiology
(1 time)
CABG (1 time)
HR (1 time)
MAP (1 time)
1994 Hemodynamic and pharmacodynamic comparison of doxacurium and high-dose vecuronium during coronary artery bypass surgery: a cost-benefit study.
82  doxercalciferol
(1 time)
Endocrinology
(1 time)
--- 2018 Doxercalciferol Alleviates Bone Deteriorations and Cartilage Degeneration in Aging Mice.
83  DOXHCl
(1 time)
Biocompatible Materials
(1 time)
EPR (1 time)
HA-NCs (1 time)
2016 Dual cellular stimuli-responsive hydrogel nanocapsules for delivery of anticancer drugs.
84  doxofylline
(1 time)
Pharmacology
(1 time)
DFO (1 time)
HSC (1 time)
2023 Doxofylline ameliorates liver fibrosis by regulating the ferroptosis signaling pathway.
85  doxorubicin (DOX)
(1 time)
Biochemistry
(1 time)
PAL (2 times)
PAZ (2 times)
DOC (1 time)
2019 Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model.
86  Doxorubicin activity
(1 time)
Medicine
(1 time)
--- 2007 [Pharmacological mechanisms of Doxorubicin activity (DOX) - current state of knowledge].
87  doxorubicin anticancer drug
(1 time)
Biochemistry
(1 time)
HeLa (1 time)
MNP (1 time)
MRI (1 time)
2022 Fabrication of a magnetic nanocarrier for doxorubicin delivery based on hyperbranched polyglycerol and carboxymethyl cellulose: An investigation on the effect of borax cross-linker on pH-sensitivity.
88  doxorubicin anticancer molecule
(1 time)
SCC-DFTB (1 time)
2020 TETT-functionalized TiO2 nanoparticles for DOX loading: a quantum mechanical study at the atomic scale.
89  doxorubicin HCl liposomal injection
(1 time)
Pharmacology
(1 time)
HCC (1 time)
MB (1 time)
UTMD (1 time)
2015 Effectiveness of localized ultrasound-targeted microbubble destruction with doxorubicin liposomes in H22 mouse hepatocellular carcinoma model.
90  doxorubicin hydrochloride drug molecules
(1 time)
Natural Science Disciplines
(1 time)
FTIR (1 time)
PL (1 time)
SDNA (1 time)
2015 Chemical and Physical Characteristics of Doxorubicin Hydrochloride Drug-Doped Salmon DNA Thin Films.
91  doxorubicin hydrochloride:paclitaxel
(1 time)
Nanotechnology
(1 time)
ACMF (1 time)
MMNPs (1 time)
2015 Enhanced cell apoptosis triggered by a multi modal mesoporous amphiphilic drug delivery system.
92  doxorubicin in the free base form
(1 time)
Biomedical Engineering
(1 time)
DLS (1 time)
GPC (1 time)
mPEG (1 time)
2009 Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn H40, poly(L-lactide) and poly(ethylene glycol) for tumor-targeted drug delivery.
93  doxorubicin or adriamycin
(1 time)
Biophysics
(1 time)
SERS (1 time)
THP-ADM (1 time)
1991 Selective analysis of antitumor drug interaction with living cancer cells as probed by surface-enhanced Raman spectroscopy.
94  doxorubicin treatment
(1 time)
Biochemistry
(1 time)
ATP (1 time)
CTR (1 time)
LDH (1 time)
2022 Protective effect of low-dose radiation on doxorubicin-induced brain injury in mice.
95  doxorubicin treatment group
(1 time)
Biomedical Research
(1 time)
CON (1 time)
DEX (1 time)
PTEN (1 time)
2020 Dexrazoxane Protects Cardiomyocyte from Doxorubicin-Induced Apoptosis by Modulating miR-17-5p.
96  Doxorubicin was administered alone
(1 time)
Cell Biology
(1 time)
--- 2012 The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and Doxorubicin.
97  doxorubicin without dexrazoxane
(1 time)
Neoplasms
(1 time)
AR (1 time)
DOX/DZX (1 time)
SAECG (1 time)
2001 Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
98  doxorubicin, a chemotherapeutic agent
(1 time)
CDT (1 time)
CT (1 time)
MRI (1 time)
2019 Upconversion-mediated ZnFe2O4 nanoplatform for NIR-enhanced chemodynamic and photodynamic therapy.
99  doxorubicin, either in its traditional
(1 time)
Neoplasms
(1 time)
ACH (1 time)
AUC (1 time)
CHF (1 time)
2007 The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.
100  Doxorubicin, PEG-LP
(1 time)
Chemistry
(1 time)
ECM (1 time)
EPR (1 time)
PEG-LP (1 time)
2016 Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.